Request Your Free White Paper Now:

"Learnings and Advice From the First Two Rounds of Medicare Drug Price Negotiations"

Download this white paper to learn more.

Access this valuable resource to explore how manufacturers can build stronger strategies for navigating the evolving Medicare Drug Price Negotiation (MDPN) landscape. Gain key insights from Lumanity, a team that has been involved in five of the first 25 drugs to undergo the MDPN process. You’ll discover:

• Why robust data and evidence will increasingly shape CMS’s negotiation outcomes
• How cross-functional collaboration across pricing, HEOR, and market access strengthens a drug’s value narrative
• Best practices for articulating comparative effectiveness and positioning against Therapeutic Alternatives (TAs)
• Why manufacturers must proactively identify and assess  the breath of available TA evidence before negotiations begin
• Strategies that clearly communicate differentiation and reinforce credibility
• Having a model that can convert and quantify assumptions into pricing scenarios like Lumanity’s in-house pricing tool is key to pressure test and optimize a submission strategy
• And more

Offered Free by: Lumanity
See All Resources from: Lumanity